Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRNP | P04156 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SPR | P35270 | 1/20 | 0.34 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120809 | 0.96 | ADRA2A (0.47) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL10321155 | 0.74 | ADRA2A (0.43) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL29791251 | 0.74 | ADRA2A (0.47) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL5464319 | 0.74 | ADRA2A (0.47) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL20406311 | 0.74 | ADRA2A (0.47) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL23193964 | 0.74 | ADRA2A (0.43) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL30849365 | 0.74 | ADRA2A (0.43) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL11961587 | 0.74 | ADRA2A (0.47) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL21471997 | 0.74 | ADRA2A (0.43) | PRNPRXFP1ADRA2AADRA2BADRA2C | |
| SCHEMBL4201272 | 0.74 | ABHD6 (0.35) | HTTKMT2AABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | EDGEWISE THERAPEUTICS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | RAYTHERA, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4594307-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| CN-119630670-A | Modulators of TNFalpha activity and uses thereof | 瑞雷拉公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025038927-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | RAYTHERA, INC. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20160200736-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-07-14 | — | — | US | disclosed |
| EP-3010914-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150252011-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC (US) | 2015-09-10 | — | — | US | disclosed |
| WO-2015125085-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2015-08-27 | — | — | WO | disclosed |
| US-9085576-B2 | Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use | AMGEN INC. (US) | 2015-07-21 | — | — | US | disclosed |
| WO-2015084692-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-06-11 | — | — | WO | disclosed |
| WO-2014202493-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-12-24 | — | — | WO | disclosed |
| US-20140275058-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | AMGEN INC. | 2014-09-18 | — | — | US | disclosed |
| US-5338740-A | Angiotensin II receptor antagonists | PFIZER INC. (US) | 1994-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200736-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | PRNP 4768/4885RXFP1 4446/4885ADRA2A 2585/4885 |
| US-20250066375-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | PRNP 936/4885RXFP1 3276/4885ADRA2A 659/4885 |
| US-12410179-B2 | Modulators of TNF alpha activity and uses thereof | TNF, TNFRSF1A, TNFRSF9 | PRNP 936/4885RXFP1 3276/4885ADRA2A 659/4885 |
| US-12509431-B2 | 1,4-dihydroquinazolinone compounds and uses thereof | TNNT2, TNNI3, TNNC1 | PRNP 4076/4885RXFP1 160/4885ADRA2A 219/4885 |
| US-20140275058-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | PRNP 286/4885RXFP1 762/4885ADRA2A 203/4885 |
| US-20250154111-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | PRNP 4084/4885RXFP1 985/4885ADRA2A 624/4885 |
| US-20250361213-A1 | 1,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, SDHA | PRNP 4084/4885RXFP1 985/4885ADRA2A 624/4885 |
| US-20250263418-A1 | MODULATORS OF TNF ALPHA ACTIVITY AND USES THEREOF | TNF, TNFRSF1A, TNFRSF9 | PRNP 936/4885RXFP1 3276/4885ADRA2A 659/4885 |
| US-20160095844-A1 | INDOLIN-2-ONE OR PYRROLO-PYRIDIN/PYRIMIDIN-2-ONE DERIVATIVES | HTR2C, OPRD1, DRD3 | PRNP 1201/4885RXFP1 1350/4885ADRA2A 246/4885 |
| US-20260028348-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, TNFRSF1A, TNFRSF9 | PRNP 1581/4885RXFP1 511/4885ADRA2A 1371/4885 |
| US-20150252011-A1 | PERFLUORINATED CYCLOPROPYL FUSED 1,3-OXAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE | BACE1, BACE2, APP | PRNP 286/4885RXFP1 762/4885ADRA2A 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.